Clinical trial · no report yet · Phase 2
DUMAS
DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors
- NCT05684276 ↗
- Active, not recruiting
- Fundación GECP
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Phase II Clinical Trial of Neo-adjuvant Chemo/Immunotherapy Followed by Adjuvant Treatment Depending on the Resection Status for the Treatment of NSCLC Patients Diagnosed With Pancoast Tumor. A Multicenter Exploratory Study
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- NSCLC; Pancoast Tumor
- Interventions
- Carboplatin; Paclitaxel; Nivolumab
- Arms
- Experimental: Neodjuvant treatment + Adjuvant maintenance treatment · Experimental
- Enrollment
- 22 (estimated)
- Primary outcomes
- Estimate progression-free survival (PFS)
- Sponsor
- Fundación GECP
- Start
- May 12, 2023
- Primary completion
- Mar 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05684276 · updated May 5, 2026